Ashley Chan

3 days ago | targetedonc.com | Ashley Chan

Encorafenib (Braftovi) plus binimetinib (Mektovi) was generally well tolerated and showed promise for adjuvant BRAF/MEK inhibition to reduce recurrence risk in patients with high-risk, stage IIB/C BRAF V600–mutated melanoma, according to data from the primary analysis of the phase 3 EORTC-2139-MG/Columbus-AD trial (NCT05270044) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1 In the intention-to-treat (ITT) population (n = 110), the 12-month recurrence-free...

4 days ago | targetedonc.com | Ashley Chan

An exploratory circulating tumor DNA (ctDNA) analysis from the phase 3 CALLA trial (NCT03830866) demonstrated that the risk of disease progression or death was reduced by at least 95% in patients with locally advanced cervical cancer who received durvalumab (Imfinzi) plus chemoradiotherapy (CRT) or CRT plus placebo who had undetectable ctDNA at the start of cycle 6. Additionally, low ctDNA at baseline was associated with improved survival outcomes in both arms compared with high ctDNA.

4 days ago | onclive.com | Ashley Chan

Encorafenib (Braftovi) added to binimetinib (Mektovi) was generally well tolerated and demonstrated the potential for adjuvant BRAF/MEK inhibition to reduce recurrence risk in patients with high-risk, stage IIB/C BRAF V600–mutant melanoma, according to data from the primary analysis of the phase 3 EORTC-2139-MG/Columbus-AD trial (NCT05270044) presented at the 2025 ASCO Annual Meeting.1 In the intention-to-treat (ITT) population (n = 110), the 12-month recurrence-free survival (RFS) rates were...

4 days ago | onclive.com | Ashley Chan

An exploratory circulating tumor DNA (ctDNA) analysis from the phase 3 CALLA trial (NCT03830866) showed that the risk of disease progression or death was reduced by at least 95% in patients with locally advanced cervical cancer treated with durvalumab (Imfinzi) plus chemoradiotherapy (CRT) or CRT plus placebo alone who had undetectable ctDNA at the start of cycle 6. Additionally, low ctDNA at baseline was associated with improved survival outcomes in both arms compared with high ctDNA.

4 days ago | targetedonc.com | Ashley Chan

One-time lifileucel (Amtagvi) therapy led to durable responses and favorable 5-year overall survival (OS) outcomes among patients with pretreated, advanced melanoma, according to the final analysis of the phase 2 C-144-01 study (NCT02360579) presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.1The objective response rate (ORR) was 31.4%; 5.9% and 25.5% of patients had complete responses (CR) and partial responses (PR), respectively.